These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23564273)

  • 41. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
    J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.
    Roncero C; Álvarez FJ
    Expert Rev Neurother; 2014 Aug; 14(8):849-65. PubMed ID: 24948428
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.
    Findling RL; Ginsberg LD; Jain R; Gao J
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):649-62. PubMed ID: 20035583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
    Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
    Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial.
    Adler LA; Alperin S; Leon T; Faraone S
    Postgrad Med; 2014 Sep; 126(5):17-24. PubMed ID: 25295646
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.
    Weisler R; Young J; Mattingly G; Gao J; Squires L; Adler L;
    CNS Spectr; 2009 Oct; 14(10):573-85. PubMed ID: 20095369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Mattingly GW; Weisler RH; Young J; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Goodman DW
    BMC Psychiatry; 2013 Jan; 13():39. PubMed ID: 23356790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder.
    Wigal SB; Raja P; Shukla A
    Expert Opin Pharmacother; 2013 Jan; 14(1):137-45. PubMed ID: 23241144
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
    Brams M; Mao AR; Doyle RL
    Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.
    Setyawan J; Guérin A; Hodgkins P; Gauthier G; Cloutier M; Wu E; Erder MH
    J Med Econ; 2013 Nov; 16(11):1275-89. PubMed ID: 24004347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
    Coghill DR; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson CS; Civil R; Dauphin M; Higgins N; Lyne A; Gasior M; Squires LA
    J Am Acad Child Adolesc Psychiatry; 2014 Jun; 53(6):647-657.e1. PubMed ID: 24839883
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
    Brams M; Giblin J; Gasior M; Gao J; Wigal T
    Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does pharmacological treatment of ADHD in adults enhance parenting performance? Results of a double-blind randomized trial.
    Waxmonsky JG; Waschbusch DA; Babinski DE; Humphrey HH; Alfonso A; Crum KI; Bernstein M; Slavec J; Augustus JN; Pelham WE
    CNS Drugs; 2014 Jul; 28(7):665-77. PubMed ID: 24796970
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
    Barner JC; Khoza S; Oladapo A
    Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder.
    Banaschewski T; Soutullo C; Lecendreux M; Johnson M; Zuddas A; Hodgkins P; Adeyi B; Squires LA; Coghill D
    CNS Drugs; 2013 Oct; 27(10):829-40. PubMed ID: 23893527
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder.
    Najib J; Wimer D; Zeng J; Lam KW; Romanyak N; Paige Morgan E; Thadavila A
    J Cent Nerv Syst Dis; 2017; 9():1179573517728090. PubMed ID: 28855799
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?
    Wigal SB; Jun A; Wong AA; Stehli A; Steinberg-Epstein R; Lerner MA
    Postgrad Med; 2010 Sep; 122(5):27-34. PubMed ID: 20861585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.